ATTRUBY™ (acoramidis)
| Full Name | ATTRUBY™ (acoramidis) |
| Drug | Acoramidis |
| Manufacturer | BridgeBio Pharma, Inc. |
| Route of Administration | Oral |
| Site of Care | Home |
| Approved Indication | ATTRUBY is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. Please see the full Prescribing Information. |
| Disease | Cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) |
| Therapeutic Area | Cardiology |
| Enrollment Form Link | ATTRUBY Enrollment Form ATTR-CM Enrollment Form (all therapies) |
| Phone Number | 888-331-6574 |
| Fax Number | 877-349-1473 |
| Product Website | www.attruby.com |
| Patient Resources | Amyloidosis Research Consortium |